A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies

Age Range:2 - Any
Start Date:September 2015
End Date:July 2016
Contact:Joseph Olaleye, BA, MPH
Phone:+1 (609) 375-9806

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% to Elimite™ Cream 5% in the Treatment of Scabies

Scabies is an infestation of the skin by the human itch mite (Sarcoptes scabiei). Diagnosis
of scabies is made based on clinical symptoms, such as nocturnal itching, and appearance and
distribution of the rash. Definitive diagnosis includes the microscopic identification of
the mite, mite eggs, or mite fecal matter in the skin. Topical permethrin is considered the
drug of choice for the treatment of scabies. It is a synthetic pyrethroid that is safe for
use in adults and children 2 months and older.

This study will evaluate the therapeutic equivalence of a generic permethrin cream 5% to
Elimite® in the Treatment of Scabies.

Inclusion Criteria:

1. Signed Informed Consent that meets all criteria of current FDA regulations.

2. Male or non-pregnant, non-lactating female at least 2 years of age or older.

3. Diagnosis of active scabies by presence of a burrow and/or typical scabietic lesions
at the classic sites of infestation.

4. Parasitological confirmation of clinical diagnosis with demonstration under light
microscope of mites and/or their products (larvae, eggs or fecal material).

5. Symptom score of 2 or 3 on a 4-point rating scale of 0-3 for nocturnal itching.

6. Women must be either 1 year post-menopausal (no menstrual periods for at least 12
months), surgically sterile, or if they are of child-bearing potential, they must:

- Have been using systemic birth control, intrauterine device, or used barrier
methods such as diaphragm plus spermicide or condom plus spermicide
consistently, at least 14 days before study cream administration.

- Had a normal menstrual cycle for the month before start of treatment.

- Have a negative urine pregnancy test result upon entry into the study.

- Agree to use a medically accepted form of birth control (oral, implant,
injectable or transdermal contraceptives, intrauterine device, condom plus
spermicide, diaphragm plus spermicide) or practice abstinence throughout the
study period.

7. Free from any systemic or dermatologic disorder that, in the opinion of the
Investigator, will interfere with the study results or increase the risk of adverse

8. Ability to apply study product to self or to other person if a child. If patient is a
child, then parent/guardian will apply study product to him/her.

Exclusion Criteria:

1. Known hypersensitivity to permethrin cream or any of its components, ragweed or
chrysanthemums, synthetic pyrethroids or pyrethrin.

2. Use of any systemic or topical acaricide 1 month before enrollment.

3. Patients with crusted/Norwegian scabies.

4. Patients with an underlying immunodeficient state (including prolonged treatment with
corticosteroids), immunosuppressive disorders requiring therapy, severe systemic
disease and history of HIV infection.

5. Any condition, medical, psychological, or social, that, in the Investigator's
opinion, would interfere with participation in the study.

6. Women who are pregnant, planning pregnancy or lactating.

7. Family members of employees of the clinic or Investigator.

8. Patients who, in the opinion of the Investigator, would be non-compliant with the
requirements of the study protocol.

9. Patients whose close personal contacts will not or are not willing to comply with
standard of care for Scabies management.

10. Patients less than 2 years of age.

11. Patients or guardians of patients, who are unable or unwilling to give informed
consent or assent respectively.

12. Receipt of any drug as part of a research study within 30 days before screening.

13. History of seizures.

14. Severe cutaneous bacterial or fungal infections requiring therapy (including systemic
and topical antibiotics) or coexisting dermatological disorder that could interfere
with the diagnosis and subsequent monitoring of scabies.

15. Treatment with systemic or topical corticosteroids less than 2 weeks and less than 1
week from enrollment, respectively.
We found this trial at
Jacksonville, FL
Click here to add this to my saved trials
Bell Gardens, California 90201
Bell Gardens, CA
Click here to add this to my saved trials
Hazleton, Pennsylvania 18201
Hazleton, PA
Click here to add this to my saved trials
Miami, FL
Click here to add this to my saved trials
Miami, Florida 33015
Miami, FL
Click here to add this to my saved trials
Pasadena, California 91105
Pasadena, CA
Click here to add this to my saved trials
Richland, Washington 99352
Richland, WA
Click here to add this to my saved trials
San Antonio, Texas 78215
San Antonio, TX
Click here to add this to my saved trials